Nutritional therapy in inflammatory bowel disease;Traitements nutritionnels au cours des MICI: Où en est-on?

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 2, 2006, Pages 262-271

  Piquet, Marie Astrid ^a   Gloro, Romain ^a   Justum, Anne Marie ^a   Reimund, Jean Marie ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CORTICOSTEROID; GLUTAMINE; METHYLPREDNISOLONE; MINERAL; OMEGA 3 FATTY ACID; PREDNISONE; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR; VITAMIN;

CROHN DISEASE; ENTERITIS; GROWTH DISORDER; HUMAN; ILEITIS; NUTRITION; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PROTEIN CALORIE MALNUTRITION; REVIEW; SHORT BOWEL SYNDROME;

EID: 33645551537     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73163-3     Document Type: Article

References (101)

1. Capristo E, Addolorato G, Mingrone G, Greco AV, Gasbarrini G. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. Am J Gastroenterol 1998;93:2411-9.
2. Harries AD, Rhodes J. Efficiency of anthropometric indicators in the assessment of protein nutrition in Crohn's disease. Hum Nutr Clin Nutr 1985;39:155-8.
3. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:423-43, IX.
4. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2001;4:561-9.
5. Schneeweiss B, Lochs H, Zauner C, Fischer M, Wyatt J, Maier-Dobersberger T, et al. Energy and substrate metabolism in patients with active Crohn's disease. J Nutr 1999;129:844-8.
6. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med 1998;243:339-47.
7. Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrugger RW, Brummer RJ. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's disease, compared with controls. Am J Gastroenterol 1999;94:410-7.
8. Al Jaouni R, Hebuterne X, Pouget I, Rampal P. Energy metabolism and substrate oxidation in patients with Crohn's disease. Nutrition 2000;16:173-8.
9. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003;98:1556-62.
10. Mingrone G, Benedetti G, Capristo E, De Gaetano A, Greco AV, Tataranni PA, et al. Twenty-four-hour energy balance in Crohn disease patients: metabolic implications of steroid treatment. Am J Clin Nutr 1998;67:118-23.
11. Al Jaouni R, Schneider SM, Piche T, Rampal P, Hebuterne X. Effect of steroids on energy expenditure and substrate oxidation in women with Crohn's disease. Am J Gastroenterol 2002;97:2843-9.
12. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998;67:919-26.
13. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002;76:1077-81.
14. De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:397-404.
15. Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 2000;95:3498-502.
16. Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003;98:112-7.
17. Maire F, Beaugerie L, Cohen M, Deschamps A, Cosnes J, Capeau J, et al. Facteurs d'hyperhomocystéinémie au cours de la maladie de Crohn. Gastroenterol Clin Biol 2001;25:745-8.
18. Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B. Antioxidant and immune status in active Crohn's disease. A possible relationship. Clin Nutr 2000;19:43-8.
19. Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000;71:807-15.
20. Wendland BE, Aghdassi E, Tam C, Carrrier J, Steinhart AH, Wolman SL, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-64.
21. Reimund JM. Stress oxydant au cours des syndromes inflammatoires chroniques. Nutr Clin Métabol 2002;16:275-84.
22. Forbes A.Review article: Crohn's disease - the role of nutritional therapy. Aliment Pharmacol Ther 2002;16 Suppl 4:48-52.
23. Jeejeebhoy KN.Clinical nutrition: 6. Management of nutritional problems of patients with Crohn's disease. CMAJ 2002;166:913-8.
24. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:307-20.
25. Hebuterne X. Nutrition artificielle: indications, modalités, résultats. Gastroenterol Clin Biol 2001;25:48-57.
26. Thompson JS, Iyer KR, DiBaise JK, Young RL, Brown CR, Langnas AN. Short bowel syndrome and Crohn's disease. J Gastrointest Surg 2003;1069-72.
27. Vanderhoof JA, Young RJ. Enteral and parenteral nutrition in the care of patients with short-bowel syndrome. Best Pract Res Clin Gastroenterol 2003;17:997-1015.
28. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
29. Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 1995;19:356-64.
30. Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996;31:267-72.
31. Zachos M, Tondeur M, Griffiths AM. Enteral nutrition therapy for inducing remission of Crohn's disease (Cochrane Review). In: Oxford: The Cochrane Library, Update Software, 2001:3.
32. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M, Vogelsang H, Sommer H, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology 1991;101:881-8.
33. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988;29:1309-15.
34. Malchow H, Steinhardt HJ, Lorenz-Meyer H, Strohm WD, Rasmussen S, Sommer H, et al. Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol 1990;25:235-44.
35. Lindor KD, Fleming CR, Burnes JU, Nelson JK, Ilstrup DM. A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc 1992;67:328-33.
36. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, Esteve M, Cabre E, Acero D, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993;34:778-82.
37. Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993;34:1198-202.
38. Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther 1997;11:735-40.
39. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000;95:735-9.
40. Leiper K, Woolner J, Mullan MM, Parker T, van d, V, Fear S, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut 2001;49:790-4.
41. Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn' s disease. Gut 1995;36:60-6.
42. Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 1990;335:816-9.
43. Rigaud D, Cosnes J, Le Quintrec Y, Rene E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 1991;32:1492-7.
44. Raouf AH, Hildrey V, Daniel J, Walker RJ, Krasner N, Elias E, et al. Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge. Gut 1991;32:702-7.
45. Park RHR, Galloway A, Danesh BJZ, Russel RI. Double-blind controlled trial of elemental and polymeric diets as primary therapy in active Crohn's disease. Eur J Gastroenterol Hepatol 1991;3:483-89.
46. Royall D, Jeejeebhoy KN, Baker JP, Allard JP, Habal FM, Cunnane SC, et al. Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome. Gut 1994;35:783-7.
47. Middleton SJ, Rucker JT, Kirby GA, Riordan AM, Hunter JO. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 1995;14:229-36.
48. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr 2002;26:98-103.
49. Modigliani R. Les formes corticorésistantes et corticodépendantes de la maladie de Crohn. Gastroenterol Clin Biol 1987;11:473-6.
50. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. JPEN J Parenter Enteral Nutr 1985;9:280-7.
51. Lerebours E, Messing B, Chevalier B, Bories C, Colin R, Bernier JJ. An evaluation of total parenteral nutrition in the management of steroid-dependent and steroid-resistant patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1986;10:274-8.
52. Sitzmann JV, Converse RL, Jr., Bayless TM. Favorable response to parenteral nutrition and medical therapy in Crohn's colitis. À report of 38 patients comparing severe Crohn's and ulcerative colitis. Gastroenterology 1990;99:1647-52.
53. Le Quintrec Y, Cosnes J, Le Quintrec M, Contou JF, Baumer P, Bellanger J, et al. L'alimentation entérale élémentaire exclusive dans les formes corticorésistantes et corticodépendantes de la maladie de Crohn. Gastroenterol Clin Biol 1987;11:477-82.
54. Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005;90:3510-6.
55. Young RJ, Vanderhoof JA. Nutrition in pediatric inflammatory bowel disease. Nutrition 2000;16:78-80.
56. Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J Pediatr 2000;136:285-91.
57. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
58. Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58.
59. Kuroki F, Iida M, Matsumoto T, Aoyagi K, Kanamoto K, Fujishima M. Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease. Dig Dis Sci 1997;42:1137-41.
60. Trebble TM, Wootton SA, May A, Erlewyn-Lajeunesse MD, Chakraborty A, Mullee MA, et al. Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. Aliment Pharmacol Ther 2003;18:433-42.
61. Desreumaux P, Dubuquoy L, Malamut G, Cheng Y. Thérapeutique nutritionnelle des maladies inflammatoires chroniques de l'intestin. Nutr Clin Métabol 2002;16:202-5.
62. Miura S, Tsuzuki Y, Hokari R, Ishii H. Modulation of intestinal immune system by dietary fat intake: relevance to Crohn's disease. J Gastroenterol Hepatol 1998;13:1183-90.
63. Nieto N, Torres MI, Rios A, Gil A. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 2002;132:11-9.
64. Campos FG, Waitzberg DL, Habr-Gama A, Logullo AF, Noronha IL, Jancar S, et al. Impact of parenteral n-3 fatty acids on experimental acute colitis. Br J Nutr 2001;87 (Supp. 1):S83-8.
65. Andoh A, Tsujikawa T, Ishizuka I, Araki Y, Sasaki M, Koyama S, et al. N-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. Int J Mol Med 2003;12:721-5
66. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996;31:778-85.
67. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
68. Tsujikawa T, Satoh J, Uda K, Ihara T, Okamoto T, Araki Y, et al. Clinical importance of n-3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn's disease. J Gastroenterol 2000;35:99-104.
69. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992;87:432-7.
70. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922-8.
71. Greenfield SM, Green AT, Teare JP, Jenkins AP, Punchard NA, Ainley CC, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993;7:159-66.
72. Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, Wiebecke B, et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 1996;41:2087-94.
73. Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 2002;16:1131-5.
74. Almallah YZ, Ewen SW, El Tahir A, Mowat NA, Brunt PW, Sinclair TS, et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol 2000;20:68-76.
75. Almallah YZ, El Tahir A, Heys SD, Richardson S, Eremin O. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest 2000;30:58-65.
76. Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999;23:7-11.
77. Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000;30:78-84.
78. Akobeng AI, Clayton PE, Miller V, Hall CM, Thomas AG. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand J Gastroenterol 2002;37:1422-7.
79. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001;3:947-54.
80. Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, Boirivant M. TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 2003;134:120-6.
81. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-9.
82. Fiocchi C. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001;108:523-6.
83. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
84. Phylactos AC, Fasoula IN, Arnaud-Battandier F, Walker-Smith JA, Fell JM. Effect of enteral nutrition on antioxidant enzyme systems and inflammation in paediatric Crohn's disease. Acta Paediatr 2001;90:883-8.
85. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A randomized controlled trial. Am J Gastroenterol 2003;98:348-53.
86. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003;17:755-73.
87. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-40.
88. Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 2003;17:741-54.
89. Tamboli CP, Caucheteux C, Cortot A, Colombel JF, Desreumaux P. Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 2003;17:805-20.
90. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
91. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
92. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of the probiotic strain Lactobacillus Johnsonii La1 in preventing recurrence after curative resection for crohn's disease - a randomized double-blind placebo-controlled trial (abstract). Gastroenterology. 2005;128(4 Suppl 2): A1-821.
93. Van Gossum A, Dewit O, Geboes K, Baert P, De Vos M, Louis E, et al. A randomized placebo-controlled clinical trial of probiotics (L. Jonhsonii, Lal®) on early endoscopic recurrence of Crohn's disease (cd) after ileo-caecal resection (abstract). Gastroenterology. 2005;128(4 Suppl 2):A1-821.
94. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
95. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
96. Kruis W, Fric P, Stolte M, and the Mutaflor Study Group. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine (abstract). Gastroenterology 2001;120 (suppl. 5):A127.
97. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
98. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 1994;35:658-64.
99. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
100. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
101. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.